COMPANY

MimiVax, LLC

HQ: Buffalo, NY source · mimivax.com ↗ · Mid-Atlantic

Location: Buffalo, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Newly Diagnosed Glioblastoma myasthenia gravis SurVaxM

Timeline

Nov 18, 2021 Trial start Phase 2: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05163080	SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)	Phase 2	Unknown status (ClinicalTrials.gov)	Nov 18, 2021	Aug 18, 2024 (estimated)

Annual award amounts. Total $464K.

Aug 31, 2022 NIH award 1R43NS124329-01A1 FY2022: $463,979 awarded for that fiscal year; activity R43 (SBIR); PI CIESIELSKI, MICHAEL J.; recipient as written: MIMIVAX, LLC, BUFFALO, NY. MV2C2 antibody as a new therapeutic for Myas source ↗